Table 2 Prevalence of thrombophilic risk factors in patients with central retinal artery occlusion and controls. Data presented as numbers and percentages of patients with results above/below the reference range
From: High prevalence of thrombophilic risk factors in patients with central retinal artery occlusion
Thrombophilic risk factor | CRAO group n = 126 | Control group n = 107 | p-value |
|---|---|---|---|
Protein C activity (< 75%), n (%) | 22 (17.5%) | 2 (1.9%) | < 0.001* |
Free protein S level (< 75%), n (%) | 25 (19.8%) | 7 (6.5%) | 0.003* |
Antithrombin activity (< 75%), n (%) | 10 (7.9%) | 4 (3.7%) | 0.18 |
Factor VIII activity (> 150%), n (%) | 26 (20.6%) | 18 (16.8%) | 0.46 |
Homocysteine (> 15 µmol/l), n (%) | 28 (22.2%) | 12 (11.2%) | 0.026* |
Anticardiolipin antibodies IgM (> 20 MPL), n (%) | 13 (10.3%) | 1 (0.9%) | 0.003* |
Anticardiolipin antibodies IgG (> 15 GPL), n (%) | 17 (13.5%) | 0 (0%) | < 0.001* |
Anti-beta-2-glycoprotein I antibodies IgM (> 20 SMU), n (%) | 16 (12.7%) | 1 (0.9%) | < 0.001* |
Anti-beta-2-glycoprotein I antibodies IgG (> 15 SGU), n (%) | 25 (19.8%) | 1 (0.9%) | < 0.001* |
Lupus anticoagulant, n (%) | 6 (4.8%) | 3 (2.8%) | 0.51 |
Factor V Leiden mutation, n (%) | heterozygosity 14 (11.1%) homozygosity 3 (2.4%) altogether 17 (13.5%) | heterozygosity 4 (3.7%) homozygosity 2 (1.9%) altogether 6 (5.6%) | 0.044* |
Factor II G20210A mutation, n (%) | heterozygosity 12 (9.5%) homozygosity 1 (0.8%) altogether 13 (10.3%) | heterozygosity 3 (2.8%) homozygosity 2 (1.9%) altogether 5 (4.7%) | 0.11 |